Compare WEAV & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEAV | CYRX |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | United States |
| Employees | N/A | 1100 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 487.7M | 419.3M |
| IPO Year | 2021 | 2008 |
| Metric | WEAV | CYRX |
|---|---|---|
| Price | $4.88 | $9.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $11.00 | ★ $12.94 |
| AVG Volume (30 Days) | ★ 1.4M | 396.2K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.50 | ★ 156.22 |
| EPS | N/A | ★ 1.40 |
| Revenue | ★ $239,024,000.00 | $176,177,000.00 |
| Revenue This Year | $17.20 | $11.06 |
| Revenue Next Year | $13.74 | $8.45 |
| P/E Ratio | ★ N/A | $6.91 |
| Revenue Growth | ★ 16.99 | N/A |
| 52 Week Low | $4.24 | $5.21 |
| 52 Week High | $11.32 | $11.45 |
| Indicator | WEAV | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.99 | 67.90 |
| Support Level | $4.85 | $9.18 |
| Resistance Level | $7.31 | $10.23 |
| Average True Range (ATR) | 0.28 | 0.43 |
| MACD | 0.06 | 0.19 |
| Stochastic Oscillator | 58.64 | 90.38 |
Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses, that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more, enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and revenue from subscription services.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.